Shared on 24 Oct 25
Analysts have recently raised their price targets for Aquestive Therapeutics, with increases up to $12 per share. They cite extended patent protection for Anaphylm and positive regulatory developments as key factors supporting a more optimistic outlook.
Shared on 09 Oct 25
Fair value Increased 5.83%Upcoming FDA Approval Will Enable Needle-Free Epinephrine Adoption
The analyst fair value estimate for Aquestive Therapeutics has been increased by $0.50 to $9.08. Analysts cite recent patent extensions and regulatory progress for Anaphylm as key drivers of the upward revision.
Shared on 01 May 25
Fair value Decreased 2.89%Upcoming FDA Approval Will Enable Needle-Free Epinephrine Adoption
Shared on 24 Apr 25
Fair value Decreased 4.44%FDA Approval And Anaphylm Launch Will Expand Global Reach
AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.
Shared on 17 Apr 25
FDA Approval And Anaphylm Launch Will Expand Global Reach
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Increased 9.78%FDA Approval And Anaphylm Launch Will Expand Global Reach
AnalystConsensusTarget made no meaningful changes to valuation assumptions.